The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart. PAH is one of five groups of pulmonary hypertension, as described by the World Health Organization (WHO). PAH develops due to the narrowing, blocking, and thickening of the pulmonary arteries.
Browse Full Global Pulmonary Arterial Hypertension Market Report With Complete TOC @ http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html
Advanced treatment of PAH includes prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. This leading therapy is aimed towards the symptoms of PAH and is not directed at the fundamental cause of PAH. In addition to the aforementioned classification of drugs, there are some other drugs prescribed to patients suffering from PAH, such as diuretics, calcium channel blockers, anticoagulants, and digoxin.
The pulmonary arterial hypertension (PAH) market was valued at US$4.04 billion in 2013 and is expected reach US$5.19 billion in 2020, expanding at a CAGR of 2.3% between 2014 and 2020.
Uptravi: A New Drug Application in Patients with Pulmonary Arterial Hypertension
Categorized on the basis of substantially applicable drug categories, the global pulmonary arterial hypertension (PAH) market has been segregated into prostacyclin analogs and prostacyclin, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the foremost to be medically endorsed by the U.S. FDA to treat PAH. Presently, epoprostenol Veletri and Flolan, treprostinil (Tyvaso, Remodulin, and...